The Patent Board, an independent provider of best practices research, tools and metrics for patent analysis and intellectual property investment, has ranked the Heska Corporation‘s Science Strength division in the top 50 of the Biotechnology industry. Heska is a provider of advanced veterinary diagnostic and other specialty veterinary products.
“We are pleased a respected third party has chosen to recognize our Science Strength,” said Dr. Robert Grieve, Heska’s Chairman and CEO. “The quality of our scientific efforts and the potential value of our substantial intellectual property value are assets we feel are often overlooked.”
Heska’s issued and pending patent portfolios primarily relate to heartworm control, flea control, allergy, infectious disease vaccines, diagnostic and detection tests, immunomodulators, instrumentation, nutrition, pain control and vaccine delivery technologies.
For more information about the Patent Board’s review of Heska go to http://online.wsj.com/mdc/public/page/2_3022-macromkt.html.